bioAffinity Technologies, Inc.: 8-K current report

US · 2026-10-06

1. Step 1 · The triggerbioAffinity reports >100% YoY CyPath Lung sales growth through Q3 2026, validating clinical adoption
2. Step 2 · Knock-onreorder velocity accelerates as initial clinical users expand to routine screening workflows and new accounts convert
3. Step 3 · Knock-ondiagnostic distributors and clinical labs face a sourcing decision — add CyPath Lung or risk losing accounts to competitors who do
4. Step 4 · Reaches youSME distributors who move early capture territorial relationships and recurring reagent revenue; laggards face exclusivity lockout by larger reference labs

The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.

Source: SEC EDGAR — Current filings

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.